Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Moreno, Rafael; Ullenhag, Gustav; Alemany, Ramon; Lövgren, Tanja; Eriksson, Emma; Loskog, Angelica

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Moreno, Rafael; Ullenhag, Gustav; Alemany, Ramon; Lövgren, Tanja; Eriksson, Emma; Loskog, Angelica.

Afiliação

Wenthe J; Uppsala University, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, 751 85 Uppsala, Sweden.
Naseri S; Uppsala University, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, 751 85 Uppsala, Sweden.
Hellström AC; Uppsala University, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, 751 85 Uppsala, Sweden.
Moreno R; IDIBELL-Institute Català d'Oncologia, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Ullenhag G; Uppsala University, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, 751 85 Uppsala, Sweden.
Alemany R; Uppsala University Hospital, Department of Oncology, 751 85 Uppsala, Sweden.
Lövgren T; IDIBELL-Institute Català d'Oncologia, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Eriksson E; Uppsala University, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, 751 85 Uppsala, Sweden.
Loskog A; Uppsala University, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, 751 85 Uppsala, Sweden.